What makes Oncimmune different?

Our understanding of the human immune system enables us to harness its sophisticated response to disease to detect disease earlier and to support the development of better therapies.

The unique combination of our core technology and understanding of the immune system, powers our ImmunoINSIGHTS service; a proprietary platform that enables life-science organisations to optimise drug development and delivery, leading to more effective, targeted as well as safer treatments for patients.

The key to improving cancer survival is early detection and optimal selection for therapy. As a company, we are driven by our passion to improve cancer survival and give people `extra time`. Oncimmune`s immuno-diagnostic test, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis.

Our strategy

Using our unique expertise and proprietary technology we aim to transform the way disease is diagnosed and treated around the world. We know that detecting the disease early can improve the ability to treat cancer and enhance chances of survival.

ImmunoINSIGHTS provides expertise in the human immune system and access to our library of over 9,000 immunogenic proteins for healthcare organisations developing new and existing treatments for more effective use in cancer, auto-immune and infectious diseases.

In addition, we are working with governments, healthcare systems and partners to provide access to our simple blood test for lung cancer as part of national and local screening programmes. Developing our EarlyCDT portfolio for other cancer types is a key aspect of our research and future growth strategy.

This strategy is being delivered through a close focus on three core aspects of our business: Operations, Technical & Research and Commercial.

We report each quarter on the progress of our strategy.

Oncimmune Holdings PLC products

Oncimmune SeroTag - Discovery Technology